Zobrazeno 1 - 10
of 161
pro vyhledávání: '"Michael A Fifer"'
Autor:
Keitaro Akita, Kenya Kusunose, Akihiro Haga, Taisei Shimomura, Yoshitaka Kosaka, Katsunori Ishiyama, Kohei Hasegawa, Michael A. Fifer, Mathew S. Maurer, Yuichi J. Shimada
Publikováno v:
Echo Research and Practice, Vol 11, Iss 1, Pp 1-10 (2024)
Abstract Background Hypertrophic cardiomyopathy (HCM) can cause myocardial fibrosis, which can be a substrate for fatal ventricular arrhythmias and subsequent sudden cardiac death. Although late gadolinium enhancement (LGE) on cardiac magnetic resona
Externí odkaz:
https://doaj.org/article/49d0f8d0e84c4c5f9f464210c3d2b890
Autor:
Bradley S. Lander, Yanling Zhao, Kohei Hasegawa, Mathew S. Maurer, Albree Tower-Rader, Michael A. Fifer, Muredach P. Reilly, Yuichi J. Shimada
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 9 (2022)
IntroductionIn hypertrophic cardiomyopathy (HCM), late gadolinium enhancement (LGE) on cardiac magnetic resonance imaging (CMR) represents myocardial fibrosis and is associated with sudden cardiac death. However, CMR requires particular expertise and
Externí odkaz:
https://doaj.org/article/1d4b77c3a8b64e2fb5174549fc803275
Autor:
Sae X. Morita, Kenya Kusunose, Akihiro Haga, Masataka Sata, Kohei Hasegawa, Yoshihiko Raita, Muredach P. Reilly, Michael A. Fifer, Mathew S. Maurer, Yuichi J. Shimada
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 8 (2021)
Genetic testing provides valuable insights into family screening strategies, diagnosis, and prognosis in patients with hypertrophic cardiomyopathy (HCM). On the other hand, genetic testing carries socio-economical and psychological burdens. It is the
Externí odkaz:
https://doaj.org/article/1f400c5201b94c7dacbe01cbf415aa73
Autor:
Mark V. Sherrid, Samuel Bernard, Nidhi Tripathi, Yash Patel, Vivek Modi, Leon Axel, Soheila Talebi, Brian B. Ghoshhajra, Danita Y. Sanborn, Muhamed Saric, Elizabeth Adlestein, Isabel Castro Alvarez, Yuhe Xia, Daniel G. Swistel, Daniele Massera, Michael A. Fifer, Bette Kim
Publikováno v:
JACC: Cardiovascular Imaging. 16:591-605
Autor:
Michael N. Young, Dhaval Kolte, Mary E. Cadigan, Elizabeth Laikhter, Kevin Sinclair, Eugene Pomerantsev, Michael A. Fifer, Thoralf M. Sundt, Robert W. Yeh, Farouc A. Jaffer
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 9, Iss 8 (2020)
Background The Heart Team approach is ascribed a Class I recommendation in contemporary guidelines for revascularization of complex coronary artery disease. However, limited data are available regarding the decision‐making and outcomes of patients
Externí odkaz:
https://doaj.org/article/943503d8a3024a9f8c1b047ac58ecdec
Autor:
Irene W. Y. Ma, Joshua D. Caplin, Aftab Azad, Christina Wilson, Michael A. Fifer, Aranya Bagchi, Andrew S. Liteplo, Vicki E. Noble
Publikováno v:
Critical Ultrasound Journal, Vol 9, Iss 1, Pp 1-8 (2017)
Abstract Background Non-invasive measures that can accurately estimate cardiac output may help identify volume-responsive patients. This study seeks to compare two non-invasive measures (corrected carotid flow time and carotid blood flow) and their c
Externí odkaz:
https://doaj.org/article/1be63c0777a047c9b9bacd7d45427aa0
Autor:
Weeranun D. Bode, Michael F. Bode, Megan Zhao, Igor Palacios, Rahul Sakhuja, Michael A. Fifer, Theofanie Mela
Publikováno v:
Journal of Interventional Cardiac Electrophysiology.
Autor:
Yuichi J. Shimada, Yoshihiko Raita, Lusha W. Liang, Mathew S. Maurer, Kohei Hasegawa, Michael A. Fifer, Muredach P. Reilly
Publikováno v:
Circulation: Genomic and Precision Medicine. 15
Background: Hypertrophic cardiomyopathy often causes major adverse cardiovascular events (MACE), for example, arrhythmias, stroke, heart failure, and sudden cardiac death. Currently, there are no models available to predict MACE. Furthermore, it rema
Autor:
Hiroo Takayama, Yuichi J. Shimada, Muredach P. Reilly, Sae X Morita, Yanling Zhao, Kohei Hasegawa, Michael A. Fifer, Mathew S. Maurer
Publikováno v:
International Heart Journal. 62:1035-1041
Septal reduction therapy (SRT) -i.e. septal myectomy and alcohol septal ablation-has been performed to treat medically refractory hypertrophic cardiomyopathy (HCM) for decades. However, it is largely unknown whether SRT prevents HCM-related cardiovas
Autor:
Martin S. Maron, Ahmad Masri, Lubna Choudhury, Iacopo Olivotto, Sara Saberi, Andrew Wang, Pablo Garcia-Pavia, Neal K. Lakdawala, Sherif F. Nagueh, Florian Rader, Albree Tower-Rader, Aslan T. Turer, Caroline Coats, Michael A. Fifer, Anjali Owens, Scott D. Solomon, Hugh Watkins, Roberto Barriales-Villa, Christopher M. Kramer, Timothy C. Wong, Sharon L. Paige, Stephen B. Heitner, Stuart Kupfer, Fady I. Malik, Lisa Meng, Amy Wohltman, Theodore Abraham
Publikováno v:
Journal of the American College of Cardiology. 81(1)
Left ventricular outflow tract (LVOT) obstruction is a major determinant of heart failure symptoms in obstructive hypertrophic cardiomyopathy (oHCM). Aficamten, a next-in-class cardiac myosin inhibitor, may lower gradients and improve symptoms in the